PBPauline Balagny

Pauline Balagny

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pauline Balagny has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Implementation of a WatchPAT‐Based Diagnostic Pathway for Obstructive Sleep Apnea in a Tertiary Hypertension Center: A Feasibility Study

    by Alexandre Boutigny, Justina Motiejunaite, Pauline Balagny, Florence Arnoult, Emmanuelle Vidal‐Petiot, Nassim Mohamedi, Justine Frija, Marie‐Pia D’ORtho

    Background: Obstructive sleep apnea (OSA) is a prevalent yet underdiagnosed in hypertension, affecting 30% to 83% of patients. Limited polysomnography access delays diagnosis. We evaluated the feasibility, diagnostic yield, and downstream management decisions of an integrated diagnostic pathway using WatchPAT 300, a peripheral arterial tonometry‐based home sleep apnea test, in a tertiary hypertension unit. Methods: In this single‐center, prospective, observational study, 200 patients underwent ambulatory OSA assessment from May 2023 through August 2025. We recorded clinical variables, peripheral arterial tonometry data, and management decisions. A subgroup underwent confirmatory in‐laboratory polysomnography. Patients were classified as none‐to‐mild OSA (peripheral apneahypopnea index <15/h) and moderate‐to‐severe OSA (≥15/h). Results: The pathway achieved 97.5% (95% CI, 94%–99%) technical success and reduced the mean time‐to‐diagnosis to 3.5±4.5 days, versus 154 days for in‐laboratory polysomnography. Over half of the cohort was triaged: ∼30% met treatment criteria directly, and 22% were ruled out. Among patients completing confirmatory polysomnography, 83% (95% CI, 61%–94%) initially classified as none‐to‐mild were reclassified as moderate‐to‐severe OSA, and 77% required treatment. Furthermore, symptoms were dissociated from severity, and Snoring‐Tired‐Observed‐Pressure‐BMI‐Age‐Gender (STOP‐Bag) association with severity did not remain significant after multiplicity correction. Conclusions: A peripheral arterial tonometry‐based home sleep apnea test‐first model is feasible and efficient, eliminating diagnostic delays. Although effective for triaging clear‐cut cases, the high reclassification rate underscores the almost mandatory role of confirmatory polysomnography for milder or equivocal results, suspected comorbid sleep disorders, or high STOP‐Bag score. These data argue against symptoms‐based screening alone to screen populations with hypertension.

  • Open Access

    AMI-Sleep: protocol for a prospective study of sleep-disordered breathing/sleep apnoea syndrome and incident cardiovascular events after acute myocardial infarction

    by Pauline Balagny, Marie-Pia D’oRtho, Laurence Berard, Alexandra Rousseau, Julie Gourmelen, Philippe Ravaud, Isabelle Durand-Zaleski, Tabassome Simon, Philippe Gabriel Steg

    Introduction Sleep-disordered breathing (SDB) and the related clinical syndrome, sleep apnoea syndrome (SAS), are highly prevalent in patients with ischaemic heart disease and often remain undiagnosed. The AMI-Sleep study will describe its prevalence in patients with acute myocardial infarction (AMI) and assess the independent contribution of the type and severity of SDB/SAS to subsequent incident cardiovascular events and mortality. Methods and analysis This prospective study will include patients hospitalised for AMI enrolled in the multicentre nationwide prospective French Cohort of Myocardial Infarction Evaluation (FRENCHIE) registry. A nightly simplified polygraphy is performed before discharge from the index AMI admission, and participants complete two self-administered sleep questionnaires. Baseline data are obtained from the FRENCHIE registry. Each participant will be subsequently followed based on data from the National Health Data System (SNDS). Over a period of 4 years, the AMI-Sleep study is expected to recruit approximately 2000 participants. Assuming at least a 10% rate of incident cardiovascular events over 1 year, there would be an estimated 200 events during the first year of follow-up that would be sufficient in multivariable analysis. The primary objective is to describe the prevalence and severity of SDB in AMI and to analyse the association between the type and severity of SDB (based on the apnoea-hypopnoea index) and the occurrence of cardiovascular events (incident acute coronary syndrome, transient ischaemic attack, stroke) or all-cause death after AMI. Secondary objectives include determining the association between the presence of SAS and coronary artery disease severity, in-hospital mortality, morbidity events, healthcare consumption and related costs. Ethics and dissemination Eligible individuals are provided with information about the AMI-Sleep study and provided written informed consent. The protocol was approved by the regional Ethics Committee (CPP Ouest II – Angers, RCB N°2018-A00719-46) on 17 February 2019, is registered on ClinicalTrials.gov (NCT04064593) and started in January 2019 with the expected publication of primary outcome results in 2025. Trial registration number ClinicalTrials.gov, NCT04064593.


  • Association of Snoring and Daytime Sleepiness With Subsequent Incident Hypertension: A Population-Based Cohort Study

    by Pauline Balagny, Emmanuelle Vidal-Petiot, Sofiane Kab, Justine Frija, Philippe Gabriel Steg, Marcel Goldberg, Marie Zins, Marie-Pia D’oRtho, Emmanuel Wiernik

    BACKGROUND: There is a strong association between obstructive sleep apnea and hypertension, but the effects of obstructive sleep apnea symptoms on the risk of incident hypertension are not well documented. The aim of this prospective study was to examine whether snoring and sleepiness are associated with incident hypertension. METHODS: Data from the French population-based CONSTANCES cohort were analyzed. Normotensive participants, aged 18 to 69 years, were included between 2012 and 2016 and screened for snoring, morning fatigue, and daytime sleepiness in 2017 using items of the Berlin Questionnaire. We used Cox models, adjusted for multiple potential confounders, including body mass index, baseline blood pressure, sleep duration, and depressive symptoms, to compute hazards ratios of incidentally treated hypertension. RESULTS: Among 34 727 subjects, the prevalence of self-reported habitual snoring, morning fatigue, and excessive daytime sleepiness (≥3× a week for each) was 23.6%, 16.6%, and 19.1%, respectively. During a median follow-up of 3.1 years (interquartile range, 3.0–3.5), the incidence of treated hypertension was 3.8%. The risk of de novo treated hypertension was higher in participants who reported habitual snoring (adjusted hazard ratio, 1.17 [95% CI, 1.03–1.32]) and excessive daytime sleepiness (adjusted hazard ratio, 1.42 [95% CI, 1.24–1.62]), and increased with the weekly frequency of symptoms, with a dose-dependent relationship ( P trend ≤0.02 for all symptoms). CONCLUSIONS: Self-reported snoring and excessive daytime sleepiness are associated with an increased risk of developing hypertension. Identification of snoring and daytime sleepiness may be a useful public health screening tool in primary care for hypertension prevention.


  • Open Access

    Prevalence, treatment and determinants of obstructive sleep apnoea and its symptoms in a population-based French cohort

    by Pauline Balagny, Emmanuelle Vidal-Petiot, Adeline Renuy, Joane Matta, Justine Frija-Masson, Philippe Gabriel Steg, Marcel Goldberg, Marie Zins, Marie-Pia D'Ortho, Emmanuel Wiernik

    Background: Obstructive sleep apnoea (OSA) is associated with increased morbidity and mortality. Although the disorder has been well studied in selected high-risk populations, few data exist on its prevalence in the general population. We aimed to assess the prevalence and determinants of OSA in France.Methods: Data from participants of the French population-based CONSTANCES cohort aged 18–69 years at inclusion and being treated for sleep apnoea or screened for OSA in 2017 using the Berlin Questionnaire were analysed. Weighted analyses were performed to provide recent and representative results in the general population.Results: Among 20 151 participants, the prevalence of treated sleep apnoea was 3.5% (95% CI 3.0–3.9%). The prevalence of untreated subjects with a positive Berlin Questionnaire was 18.1% (95% CI 17.3–19.2%) for a total weighted prevalence of treated sleep apnoea or high risk of OSA of 20.9% (95% CI 20.0–21.9%). Regarding prevalence of OSA symptoms, it was 37.2% (95% CI 36.1–38.3%) for severe snoring and 14.6% (95% CI 13.8–15.5%) for hypersomnolence. In multivariable logistic regression analysis, male sex, age, previous cardiovascular events, smoking, low educational level, low physical activity and depressive symptoms were associated with having either treated sleep apnoea or a positive Berlin Questionnaire.Conclusion: In this large French population-based cohort, one in five participants had a high likelihood of OSA, whereas only 3.5% were treated for the disorder, suggesting major underdiagnosis in the general population. OSA diagnosis should be considered more often in people with risk factors such as depressive symptoms as well as unhealthy behaviours and socioeconomic conditions.


  • Syndrome d’apnées obstructives du sommeil : prévalence et facteurs sociodémographiques et de style de vie associés dans la cohorte Constances

    by Justine Frija-Masson, Joane Matta, Emmanuel Wiernik, Pauline Balagny, Gabriel Steg, Céline Ribet, Marcel Goldberg, Marie Zins, Marie-Pia D’oRtho

  • Syndrome d’apnées obstructives du sommeil : prévalence et facteurs sociodémographiques et de style de vie associés dans la cohorte Constances

    by J. Matta, E. Wiernik, J. Frija-Masson, P. Balagny, G. Steg, C. Ribet, M. Goldberg, M. Zins, M.P. D’oRtho